The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | CAR-T gives sustained disease control in R/R adult DLBCL: updated JULIET analysis
The JULIET trial (NCT02445248) was a multicenter, global, pivotal Phase II trial of tisagenlecleucel in adults with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Here, Richard Thomas Maziarz, MD, of the Knight Cancer Institute, Oregon Health & Science University, Portland, OR, provides an updated analysis of the trial, with a median of 19 months follow-up, revealing promising sustained disease control with this anti-CD19 cellular therapy. In addition, Prof. Maziarz gives his insight into the more standardized grading of toxicities that is emerging, and what this means for trial results. This interview was recorded at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
